Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

The Effects of a Remote-Based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial.

Santa-Maria CA, Coughlin JW, Sharma D, Armanios M, Blackford AL, Schreyer C, Dalcin A, Carpenter A, Jerome GJ, Armstrong DK, Chaudhry M, Cohen GI, Connolly RM, Fetting J, Miller RS, Smith KL, Snyder C, Wolfe A, Wolff AC, Huang CY, Appel LJ, Stearns V.

Clin Cancer Res. 2020 Feb 18. pii: clincanres.2935.2019. doi: 10.1158/1078-0432.CCR-19-2935. [Epub ahead of print]

PMID:
32071117
2.

Pathogenic Germline Variants in Patients With Metastatic Breast Cancer.

Stuttgen K, Croessmann S, Fetting J, Stearns V, Nunes R, Connolly RM, Park BH.

JAMA Oncol. 2019 Aug 29. doi: 10.1001/jamaoncol.2019.3116. [Epub ahead of print] No abstract available.

PMID:
31465090
3.

Sharing in care: engaging care partners in the care and communication of breast cancer patients.

Wolff JL, Aufill J, Echavarria D, Heughan JA, Lee KT, Connolly RM, Fetting JH, Jelovac D, Papathakis K, Riley C, Stearns V, Thorner E, Zafman N, Levy HP, Dy SM, Wolff AC.

Breast Cancer Res Treat. 2019 Aug;177(1):127-136. doi: 10.1007/s10549-019-05306-9. Epub 2019 Jun 4.

PMID:
31165374
4.

A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.

Santa-Maria CA, Bardia A, Blackford AL, Snyder C, Connolly RM, Fetting JH, Hayes DF, Jeter SC, Miller RS, Nguyen A, Quinlan K, Rosner GL, Slater S, Storniolo AM, Wolff AC, Zorzi J, Henry NL, Stearns V.

Breast Cancer Res Treat. 2018 Aug;171(1):121-129. doi: 10.1007/s10549-018-4811-1. Epub 2018 May 11.

5.

Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.

Litvak A, Batukbhai B, Russell SD, Tsai HL, Rosner GL, Jeter SC, Armstrong D, Emens LA, Fetting J, Wolff AC, Silhy R, Stearns V, Connolly RM.

Cancer. 2018 May 1;124(9):1904-1911. doi: 10.1002/cncr.31260. Epub 2018 Jan 30.

6.

Mutational profiles of breast cancer metastases from a rapid autopsy series reveal multiple evolutionary trajectories.

Avigdor BE, Cimino-Mathews A, DeMarzo AM, Hicks JL, Shin J, Sukumar S, Fetting J, Argani P, Park BH, Wheelan SJ.

JCI Insight. 2017 Dec 21;2(24). pii: 96896. doi: 10.1172/jci.insight.96896.

7.

Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.

Kim HS, Umbricht CB, Illei PB, Cimino-Mathews A, Cho S, Chowdhury N, Figueroa-Magalhaes MC, Pesce C, Jeter SC, Mylander C, Rosman M, Tafra L, Turner BM, Hicks DG, Jensen TA, Miller DV, Armstrong DK, Connolly RM, Fetting JH, Miller RS, Park BH, Stearns V, Visvanathan K, Wolff AC, Cope L.

J Clin Oncol. 2016 Dec 20;34(36):4390-4397. Epub 2016 Oct 31.

8.

Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.

Connolly RM, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater SA, Powers P, Wolff AC, Fetting JH, Brufsky A, Piekarz R, Ahuja N, Laird PW, Shen H, Weisenberger DJ, Cope L, Herman JG, Somlo G, Garcia AA, Jones PA, Baylin SB, Davidson NE, Zahnow CA, Stearns V.

Clin Cancer Res. 2017 Jun 1;23(11):2691-2701. doi: 10.1158/1078-0432.CCR-16-1729. Epub 2016 Dec 15.

9.

TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.

Connolly RM, Leal JP, Goetz MP, Zhang Z, Zhou XC, Jacobs LK, Mhlanga J, O JH, Carpenter J, Storniolo AM, Watkins S, Fetting JH, Miller RS, Sideras K, Jeter SC, Walsh B, Powers P, Zorzi J, Boughey JC, Davidson NE, Carey LA, Wolff AC, Khouri N, Gabrielson E, Wahl RL, Stearns V.

J Nucl Med. 2015 Jan;56(1):31-7. doi: 10.2967/jnumed.114.144741. Epub 2014 Dec 4.

10.

Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.

Tevaarwerk AJ, Wang M, Zhao F, Fetting JH, Cella D, Wagner LI, Martino S, Ingle JN, Sparano JA, Solin LJ, Wood WC, Robert NJ.

J Clin Oncol. 2014 Dec 10;32(35):3948-58. doi: 10.1200/JCO.2014.55.6993. Epub 2014 Oct 27.

11.

A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.

Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram JN, Dauses T, Fetting J, Duus EM, Atay-Rosenthal S, Ye X, Wolff AC, Stearns V, Jaffee EM, Emens LA.

Cancer Immunol Res. 2014 Oct;2(10):949-61. doi: 10.1158/2326-6066.CIR-14-0058. Epub 2014 Aug 12.

12.

FOXD1 promotes nephron progenitor differentiation by repressing decorin in the embryonic kidney.

Fetting JL, Guay JA, Karolak MJ, Iozzo RV, Adams DC, Maridas DE, Brown AC, Oxburgh L.

Development. 2014 Jan;141(1):17-27. doi: 10.1242/dev.089078. Epub 2013 Nov 27.

13.

Bone morphogenetic protein signaling in nephron progenitor cells.

Oxburgh L, Brown AC, Muthukrishnan SD, Fetting JL.

Pediatr Nephrol. 2014 Apr;29(4):531-6. doi: 10.1007/s00467-013-2589-2. Epub 2013 Aug 20. Review.

14.

Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.

Rudek MA, Connolly RM, Hoskins JM, Garrett-Mayer E, Jeter SC, Armstrong DK, Fetting JH, Stearns V, Wright LA, Zhao M, Watkins SP Jr, McLeod HL, Davidson NE, Wolff AC.

Breast Cancer Res Treat. 2013 May;139(1):135-43. doi: 10.1007/s10549-013-2516-z. Epub 2013 Apr 16.

15.

Role for compartmentalization in nephron progenitor differentiation.

Brown AC, Muthukrishnan SD, Guay JA, Adams DC, Schafer DA, Fetting JL, Oxburgh L.

Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4640-5. doi: 10.1073/pnas.1213971110. Epub 2013 Mar 4.

16.

GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.

Cimino-Mathews A, Subhawong AP, Illei PB, Sharma R, Halushka MK, Vang R, Fetting JH, Park BH, Argani P.

Hum Pathol. 2013 Jul;44(7):1341-9. doi: 10.1016/j.humpath.2012.11.003. Epub 2013 Jan 31.

17.

Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years.

Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, Davidson N, Goldstein LJ, Miller KD, Sparano JA.

Cancer. 2013 Mar 15;119(6):1140-8. doi: 10.1002/cncr.27819. Epub 2012 Oct 12.

18.

Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer.

Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Fetting J, Davidson NE.

Cancer. 2012 Dec 1;118(23):5937-46. doi: 10.1002/cncr.27527. Epub 2012 Aug 27.

19.

Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.

Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, Zorzi J, Jeter SC, Oliver GR, Fetting J, Emens L, Riley C, Stearns V, Diehl F, Angenendt P, Huang P, Cope L, Argani P, Murphy KM, Bachman KE, Greshock J, Wolff AC, Park BH.

Clin Cancer Res. 2012 Jun 15;18(12):3462-9. doi: 10.1158/1078-0432.CCR-11-2696. Epub 2012 Mar 15.

20.

Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy.

Cimino-Mathews A, Hicks JL, Illei PB, Halushka MK, Fetting JH, De Marzo AM, Park BH, Argani P.

Hum Pathol. 2012 Jul;43(7):1003-11. doi: 10.1016/j.humpath.2011.08.007. Epub 2011 Dec 10.

21.

A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer.

Higgins MJ, Prowell TM, Blackford AL, Byrne C, Khouri NF, Slater SA, Jeter SC, Armstrong DK, Davidson NE, Emens LA, Fetting JH, Powers PP, Wolff AC, Green H, Thibert JN, Rae JM, Folkerd E, Dowsett M, Blumenthal RS, Garber JE, Stearns V.

Breast Cancer Res Treat. 2012 Feb;131(3):915-24. doi: 10.1007/s10549-011-1858-7. Epub 2011 Nov 11.

22.

MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors.

Singhi AD, Cimino-Mathews A, Jenkins RB, Lan F, Fink SR, Nassar H, Vang R, Fetting JH, Hicks J, Sukumar S, De Marzo AM, Argani P.

Mod Pathol. 2012 Mar;25(3):378-87. doi: 10.1038/modpathol.2011.171. Epub 2011 Nov 4.

23.

Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer.

Bardia A, Arieas ET, Zhang Z, Defilippis A, Tarpinian K, Jeter S, Nguyen A, Henry NL, Flockhart DA, Hayes DF, Hayden J, Storniolo AM, Armstrong DK, Davidson NE, Fetting J, Ouyang P, Wolff AC, Blumenthal RS, Ashen MD, Stearns V.

Breast Cancer Res Treat. 2012 Feb;131(3):907-14. doi: 10.1007/s10549-011-1843-1. Epub 2011 Nov 1.

24.

Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.

Prowell TM, Blackford AL, Byrne C, Khouri NF, Dowsett M, Folkerd E, Tarpinian KS, Powers PP, Wright LA, Donehower MG, Jeter SC, Armstrong DK, Emens LA, Fetting JH, Wolff AC, Garrett-Mayer E, Skaar TC, Davidson NE, Stearns V.

Cancer Prev Res (Phila). 2011 Dec;4(12):1993-2001. doi: 10.1158/1940-6207.CAPR-11-0154. Epub 2011 Sep 1.

25.

Isolation and culture of cells from the nephrogenic zone of the embryonic mouse kidney.

Brown AC, Blank U, Adams DC, Karolak MJ, Fetting JL, Hill BL, Oxburgh L.

J Vis Exp. 2011 Apr 22;(50). pii: 2555. doi: 10.3791/2555.

26.

BMP signaling in the nephron progenitor niche.

Oxburgh L, Brown AC, Fetting J, Hill B.

Pediatr Nephrol. 2011 Sep;26(9):1491-7. doi: 10.1007/s00467-011-1819-8. Epub 2011 Mar 4. Review.

27.

Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.

Connolly RM, Rudek MA, Garrett-Mayer E, Jeter SC, Donehower MG, Wright LA, Zhao M, Fetting JH, Emens LA, Stearns V, Davidson NE, Baker SD, Wolff AC.

Breast Cancer Res Treat. 2011 May;127(1):153-62. doi: 10.1007/s10549-011-1413-6. Epub 2011 Feb 25.

28.

Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer.

Chumsri S, Jeter S, Jacobs LK, Nassar H, Armstrong DK, Emens LA, Fetting JH, Lange JR, Riley C, Tsangaris TN, Wolff AC, Zellars R, Zhang Z, Stearns V.

Clin Breast Cancer. 2010 Feb;10(1):40-5. doi: 10.3816/CBC.2010.n.005.

PMID:
20133257
29.

Severe prolonged cholestatic hepatitis caused by exemestane.

Bao T, Fetting J, Mumford L, Zorzi J, Shahverdi K, Jeter S, Herlong F, Stearns V, Lee L.

Breast Cancer Res Treat. 2010 Jun;121(3):789-91. doi: 10.1007/s10549-009-0576-x. Epub 2009 Oct 16. No abstract available.

30.

Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.

Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC, Stearns V, Disis ML, Ye X, Piantadosi S, Fetting JH, Davidson NE, Jaffee EM.

J Clin Oncol. 2009 Dec 10;27(35):5911-8. doi: 10.1200/JCO.2009.23.3494. Epub 2009 Oct 5.

32.

African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women.

Balmanoukian A, Zhang Z, Jeter S, Slater S, Armstrong DK, Emens LA, Fetting JH, Wolff AC, Davidson NE, Jacobs L, Lange J, Tsangaris TN, Zellars R, Gabrielson E, Stearns V.

J Clin Oncol. 2009 Aug 1;27(22):e35-7; author reply e38-9. doi: 10.1200/JCO.2008.21.5509. Epub 2009 Jun 29. No abstract available.

33.

Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer.

Zellars RC, Stearns V, Frassica D, Asrari F, Tsangaris T, Myers L, DiPasquale S, Lange JR, Jacobs LK, Emens LA, Armstrong DK, Fetting JH, Garrett-Mayer E, Davidson NE, Wolff AC.

J Clin Oncol. 2009 Jun 10;27(17):2816-22. doi: 10.1200/JCO.2008.20.0139. Epub 2009 Mar 30.

34.

Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases.

Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, Teo WW, Griffin C, Fetting J, Davidson NE, De Marzo AM, Hicks JL, Chitale D, Ladanyi M, Sukumar S, Argani P.

Clin Cancer Res. 2008 Apr 1;14(7):1938-46. doi: 10.1158/1078-0432.CCR-07-4082.

35.

Pulling the trigger.

Meyskens FL Jr, Fetting JH.

J Clin Oncol. 2004 Sep 1;22(17):3644-5. No abstract available.

PMID:
15337815
36.

Opposing inputs by Hedgehog and Brinker define a stripe of hairy expression in the Drosophila leg imaginal disc.

Kwon C, Hays R, Fetting J, Orenic TV.

Development. 2004 Jun;131(11):2681-92. Epub 2004 May 5.

37.

A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin.

Emens LA, Armstrong D, Biedrzycki B, Davidson N, Davis-Sproul J, Fetting J, Jaffee E, Onners B, Piantadosi S, Reilly RT, Stearns V, Tartakovsky I, Visvanathan K, Wolff A.

Hum Gene Ther. 2004 Mar;15(3):313-37. No abstract available.

PMID:
15018740
38.

A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer.

Wolff AC, Armstrong DK, Fetting JH, Carducci MK, Riley CD, Bender JF, Casero RA Jr, Davidson NE.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5922-8.

39.

Can you cure him, for the baby's sake?

Mehta P, Fetting J.

J Clin Oncol. 2003 Nov 1;21(21):4064-5. No abstract available.

PMID:
14581431
40.

Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.

Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM.

N Engl J Med. 2003 Jul 3;349(1):17-26.

41.
42.

Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells.

van der Wall E, Horn T, Bright E, Passos-Coehlo JL, Bond S, Clarke B, Altomonte V, McIntyre K, Vogelsang G, Noga SJ, Davis JM, Thomassen J, Ohly KV, Lee SM, Fetting J, Armstrong DK, Davidson NE, Hess AD, Kennedy MJ.

Br J Cancer. 2000 Dec;83(11):1405-11.

43.

A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer.

Dees EC, O'Reilly S, Goodman SN, Sartorius S, Levine MA, Jones RJ, Grochow LB, Donehower RC, Fetting JH.

Cancer Invest. 2000;18(6):521-9.

PMID:
10923100
44.

Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG).

Fairclough DL, Fetting JH, Cella D, Wonson W, Moinpour CM.

Qual Life Res. 1999 Dec;8(8):723-31.

PMID:
10855346
45.

A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer.

Subramanyan S, Abeloff MD, Bond SE, Davidson NE, Fetting JH, Gordon GB, Kennedy MJ.

Cancer Chemother Pharmacol. 1999;43(6):497-502.

PMID:
10321510
46.

Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.

Mikhak B, Zahurak M, Abeloff MD, Fetting JH, Davidson NE, Donehower RC, Waterfield W, Kennedy MJ.

Cancer. 1999 Feb 15;85(4):899-904.

PMID:
10091768
47.

Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.

Fetting JH, Gray R, Fairclough DL, Smith TJ, Margolin KA, Citron ML, Grove-Conrad M, Cella D, Pandya K, Robert N, Henderson IC, Osborne CK, Abeloff MD.

J Clin Oncol. 1998 Jul;16(7):2382-91.

PMID:
9667255
48.

The effect of aging on the utilization of chemotherapy for metastatic breast cancer: a population-based study.

Fetting JH, Comstock GW, Eby S, Huelskamp AM, Sullivan SA, Zahurak M, Gerber J, Kass FH, Smith R.

Cancer Invest. 1997;15(3):199-203.

PMID:
9171852
49.

Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology.

Bennett CL, Smith TJ, Weeks JC, Bredt AB, Feinglass J, Fetting JH, Hillner BE, Somerfield MR, Winn RJ.

J Clin Oncol. 1996 Sep;14(9):2511-20.

PMID:
8823330
50.

Supplemental Content

Loading ...
Support Center